Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-Based Virtual Screening with the Inhibitor-Constrained Refined Homology Model

P90 ribosomal S6 kinase 2 (RSK2), which was shown to be overexpressed in human cancers, is a serine/threonine kinase and a potential target for cancer treatment. RSK2 comprises two terminal kinase domains (NTKD and CTKD) that can be inhibited by binding with different types of inhibitors at the ATP binding sites. In the absence of a crystal structure of RSK2, we constructed a model for the 3D structure of the RSK2 NTKD by homology modeling and stepwise constrained refinement with the reported inhibitors using a molecular docking method. Structure-based virtual screening was subsequently performed against a library containing commercially available compounds using the refined model. This resulted in the identification of seven novel RSK2 inhibitors with IC₅₀ values ranging from 2.4 to 14.45 μM.

[1]  R. Touraine,et al.  A syndromic form of X-linked mental retardation: the Coffin-Lowry syndrome , 2002, European Journal of Pediatrics.

[2]  J. Blenis,et al.  Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Zigang Dong,et al.  Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2 , 2008, Nature Structural &Molecular Biology.

[4]  T. Sturgill,et al.  Characterization of the p90 Ribosomal S6 Kinase 2 Carboxyl-terminal Domain as a Protein Kinase* , 2002, The Journal of Biological Chemistry.

[5]  A. Hanauer,et al.  Coffin–Lowry syndrome , 2010, European Journal of Human Genetics.

[6]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[7]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[8]  T. Nguyen.  Targeting RSK: an overview of small molecule inhibitors. , 2008, Anti-cancer agents in medicinal chemistry.

[9]  Timothy M. Errington,et al.  The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. , 2005, Cancer research.

[10]  Michael E. Greenberg,et al.  Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase , 1996, Science.

[11]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[12]  Ole Winther,et al.  RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. , 2009, Molecular cell.

[13]  A. Burlingame,et al.  Transcription Factor Phosphorylation by pp90 rsk2 , 1999, The Journal of Biological Chemistry.

[14]  Yong-Yeon Cho,et al.  A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. , 2009, Cancer research.

[15]  Hualiang Jiang,et al.  SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. , 2011, Journal of medicinal chemistry.

[16]  J. Blenis,et al.  A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Rick Gussio,et al.  Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. , 2006, Bioorganic & medicinal chemistry.

[18]  A. Alberti,et al.  Identification of novel mutations in patients with Coffin-Lowry syndrome by a denaturing HPLC-based assay. , 2005, Clinical chemistry.

[19]  Yong-Yeon Cho,et al.  The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. , 2005, Cancer research.

[20]  T. Ganesan,et al.  p90 Ribosomal S6 kinases‐ eclectic members of the human kinome , 2007 .

[21]  S. Gammeltoft,et al.  Activation of p90Rsk1 Is Sufficient for Differentiation of PC12 Cells , 2004, Molecular and Cellular Biology.

[22]  J M Thornton,et al.  Validation of protein models derived from experiment. , 1998, Current opinion in structural biology.

[23]  C. Allis,et al.  Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. , 1999, Science.

[24]  A. Jezela-Stanek,et al.  Four novel RSK2 mutations in females with Coffin-Lowry syndrome. , 2010, European journal of medical genetics.

[25]  M. Schwab,et al.  Bub1 is activated by the protein kinase p90Rsk during Xenopus oocyte maturation , 2001, Current Biology.